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Abstract  
Adults with compromised liver function are inherently deficient and especially vulnerable to the 
consequences of vitamin D deficiency. Consequences of vitamin D deficiency include liver 
disease progression, infection, and graft failure.  A vitamin D supplementation protocol is 
proposed to systematically optimize serum vitamin D levels in both pre and post liver 
transplanted patients. This quasi-experimental study used convenience sampling for 45 post  
liver transplant patients at a large academic facility. The measurable outcome in the three-month 
study was the serum 25-hydroxy vitamin D levels post supplementation protocol. Seventy-eight 
percent of patients reached minimum guideline levels using the protocol with an average 
increase of serum vitamin D of 13.8ng/mL. Long-term outcomes of clinical significance may 
include decreased incidence of acute cellular graft rejection and infections in the immune-
compromised patient. Optimizing vitamin D in vulnerable patient populations such as chronic 
liver disease and the immune-suppressed post-transplanted patient has the potential to curtail 
complications of vitamin D deficiency. As a result, employing a vitamin D protocol can have a 
favorable impact on patient quality of life, safety, and healthcare spending. 
Keywords: vitamin D, ergocalciferol, cholecalciferol, liver disease, vitamin D deficiency, 
clinical guidelines, metabolic syndrome, hepatic osteodystrophy, non-alcoholic fatty liver 
disease, mortality, and sustained virologic response 
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A Vitamin D Protocol Post Liver Transplantation  
Vitamin D deficiency (VDD) is endemic among patients with end-stage liver disease 
listed for transplantation (Abu-Mouch, Fireman, Jarchovsky, Zeina, & Assy, 2011; Chaney, 
Heckman, Diehl, Meek, & Keaveny, 2015; Stein & Shane, 2011; Zhang et al., 2016) and in those 
with liver disease.  This deficiency has been reported as high as 91% (Chaney et al., 2015; 
Choudhary et al., 2011). Vitamin D (VD) has a number of pleiotropic effects including anti-
inflammatory properties, anti-apoptosis, anti-fibrosis, regulation of function in the kidney, heart, 
and immune system, and it maintains homeostasis by regulation of hormone secretion, cell 
proliferation, and differentiation (Lai & Fang, 2013).  Research outlines the merits of vitamin D 
supplementation (VDS) in patients with chronic liver disease (CLD) of various etiologies (Anty 
et al., 2014; DiCarlo et al., 2015; Eliades & Spyrou, 2015; Fernandez-Fernandez, Linares-Torres, 
Matias, Jorquera-Plaza, & Olcoz-Goni, 2015; Stokes, Krawczyk, Reichel, Lammert, & 
Grunhage, 2014). Cited benefits can be stratified into areas such as the immune system (innate 
and adaptive), metabolic disorders, bone health, and all-cause mortality (Iruzubieta, Teran, 
Crespo, & Fabrega, 2014; Stokes, Volmer, Grunhage, & Lammert, 2013; Villar, Del Campo, 
Ranchal, Lampe, & Romero-Gomez, 2013).  
Clinical practice guidelines from three different professional organizations recommend 
VDS in high-risk populations such as adults with CLD and post liver transplantation, suggesting 
detailed dosing schedules (Lucey et al., 2013; Holick et al., 2011). Currently, patients are 
sporadically supplemented with weekly doses of ergocalciferol (vitamin D2) in the student 
investigator’s (SI) practice. However, cholecalciferol (vitamin D3) has been shown to have a 
more effective increase on serum 25(OH)D (Logan, Gray, Peddie, Harper, & Houghton, 2013)    
Mangoo-Karim et al., 2015; Osborn & Germann, 2011). 
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Project Background  
Significance of the Topic  
Vitamin D deficiency (VDD) is prevalent in patients with liver failure, as well as in organ 
recipients, and can persist long after transplantation (Courbebaisse et al., 2014; Thiem et al., 
2013). Immune system compromise, hyperparathyroidism, bone loss, fracture, muscle weakness, 
falls, insulin resistance, hypertension, and malignancy have all been associated with VDD (Stein 
et al., 2009). In patients with cirrhosis, the incidence of severe VDD (<25ng/mL) increases with 
worsening synthetic liver dysfunction (Kitson & Roberts, 2012; Zhang et al., 2016). With respect 
to patient safety, therapeutic VD levels have been shown to increase strength (Bischoff-Ferrari et 
al., 2004; Bischoff-Ferrari et al., 2012), and although it has not shown to reduce falls in the 
vitamin D-optimized population, it is thought to have an effect on muscle strength in those that 
are severely deficient (Gillespie et al., 2012). 
Economic significance. Vitamin D can confer health benefits to the general population 
as well as reduce the risks that are consequential of vitamin D deficiency (Grant et al., 2009). 
Diseases such as diabetes mellitus, cardiovascular disease, various cancers, bacterial and viral 
infections, and immune system dysfunction involve vitamin D deficiency and have a tremendous 
economic impact on society (Grant et al., 2009). With numerous comorbidities involving vitamin 
D deficiency, the financial burden of sub-optimal serum levels has a significant economic effect. 
Economic burden represents direct medical costs such as screening and treatment, as well as 
indirect costs involving the effects of comorbidities and mortality (Grant et al., 2009). Successful 
optimization of serum 25(OH)D levels of patients to 40 ng/mL has the potential to reduce the 
overall direct economic strain of disease by 11.4%, or $118 million and would decrease the 
indirect economic obligation of disease by $93 million (Grant et al., 2009). In turn, this would 
A VITAMIN D PROTOCOL POST LIVER TRANSPLANTATION 5 
result in a comprehensive reduction in economic burden of disease by 17.7%, or $211 million 
(Grant et al., 2009). 
Policy and health system significance. Vitamin D deficiency is considered endemic, 
and changes in public policy are in order to help at-risk groups maintain an optimal level through 
appropriate sunlight exposure, fortified foods, and supplementation (Holick, 2010). Currently, 
the United States Preventative Services Task Force (USPSTF) lists the evidence for testing 
vitamin D in asymptomatic adults as “inconclusive” ("USPSTF," 2014). However, this is not 
always an accurate indicator of who needs to be tested. In a cohort study of healthy medical 
residents and students at a Boston hospital, 32% were found to be VD deficient despite daily 
intake of VD (400IU) and a glass of vitamin D fortified milk (Holick, 2010). Public policies are 
needed to ensure sufficient intake of vitamin D in all industrialized countries (Holick, 2010). 
Local Issue of Vitamin D Deficiency  
It is well established that compromised liver function will affect an individual’s ability to 
synthesize VD (Arteh, Narra, & Nair, 2010; Autier & Gandini, 2007; Krol et al., 2014), thus 
causing vitamin D deficiency in patients with liver disease. The targeted population in this 
Doctor of Nursing Practice (DNP) project are transplanted patients with sub-optimal serum 
25(OH)D levels. The intention is to supplement these patients who are especially at risk for 
complications of the VDD. The pre-transplant population has advanced disease, and the post 
population is vulnerable to infections and graft rejection (Kitson & Roberts, 2012). 
Considering Diversity  
The city of Los Angeles is home to one of the most diverse populations in the country. 
The demographics of the liver transplant service at the study site, while not representing all 
communities, reflects much of the city’s diverse population. The Hispanic population is the 
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largest minority contingent, and language barriers are prevalent. Therefore, education and social 
support dynamics must be considered. Additionally, darker skin is more common in this 
population and interferes with natural vitamin D absorption from the sun (Mangoo-Karim et al., 
2015). Despite living in the solar-rich environment of southern California, pre-treatment levels of 
vitamin D tend to be lower in darker-skinned patients than in Caucasians (Mangoo-Karim et al., 
2015). The Asian population born outside of the US brings an otherwise rare etiology for 
transplantation which is hepatitis B. Patients with an etiology of hepatitis B must take life-long 
medications that are known to adversely affect bone health and place them at risk for fractures 
(Holick et al., 2011). 
Problem and Purpose 
Problem Statement  
End-stage liver disease creates a host of comorbidities, one being compromised 
metabolism of vitamin D leading to severely deficient levels. Although studies have highlighted 
numerous benefits that supplementation would confer in this population, few venture to 
recommend standardizing a protocol that would assure therapeutic levels. This project 
encompassed a vitamin D3 (cholecalciferol) supplementation protocol that was developed and 
implemented for patients with liver disease prior to transplantation with the intention of 
continuing surveillance/supplementation post transplantation. Although both pre and post 
transplanted patients receive supplementation, this study focused only on the post-transplanted 
patient’s response to this dosing schedule. This protocol replaces the previously used vitamin D2 
(ergocalciferol) dosing as evidence shows the superiority of cholecalciferol in improving serum 
25(OH)D levels (Logan et al., 2013; Osborn & Germann, 2011). 
Catalyzing Change 
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Vitamin D has long been sporadically checked in the SI’s patient population. On the in-
patient area of the department, the nurse practitioners are the primary providers that initiate and 
discontinue medications. Awareness of vitamin D deficiency has not been optimal, therefore 
leading to patients with sub-optimal levels, as they are not always evaluated in their respective 
clinics. A combination of a persistent and thorough registered dietician along with the SI’s goal 
of translating evidence into practice provided the foundation for the current DNP project.  
The primary purpose of this DNP project was to employ a vitamin D3 dosing protocol 
developed from the input of a multi-disciplinary team and subsequently assess serum levels for 
the protocol’s effectiveness in patients with end-stage liver failure and post liver transplantation 
in an effort to meet recommended guidelines in these populations. 
Facilitators and Barriers  
There were more facilitators than barriers in this DNP project. The facilitators included 
inpatient providers on the liver transplant service, the registered dietician, and liver transplant 
coordinators. Vitamin D3 is safe and inexpensive, and VD2 is already used in the patient 
population at the host institution, albeit sporadically. The identified subjects were seen in the 
outpatient liver clinic and had their 25(OH)D level drawn along with their standard labs. The 
nutritionist, and liver transplant coordinators in this setting were additional liaisons to the student 
investigator as well as the main facilitators. Barriers included lack of knowledge about value of 
project amongst inpatient providers, patient compliance, attitude that it is a low priority 
intervention in the patient’s care, and buy-in of providers in outpatient setting. There were no 
institutional barriers. 
Review of the Evidence 
PICOTS  
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In end-stage liver disease patients post transplanted who are deficient in vitamin D, does 
the implementation of a vitamin D3 protocol improve serum vitamin D level [25(OH)D] to 
recommended levels during three months on the liver transplant service at a large academic 
medical center in large metropolitan city? 
Search Strategy  
The primary databases for the literature search were Medline (PubMed), the Cumulative 
Index to Nursing and Allied Health Literature (CINAHL), and Cochrane for studies that matched 
any combination of the following keywords: vitamin D, liver disease, vitamin D deficiency, 
calcidol, clinical guidelines, metabolic syndrome, hepatic osteodystrophy, non-alcoholic fatty 
liver disease, mortality, and sustained virologic response. Google Scholar was crosschecked for 
additional research. Articles published in the last five years were reviewed first, and if highly 
relevant supporting articles were found to be older, they were also included up to ten years past. 
Studies were reviewed and those that discussed the relationship between vitamin D deficiency 
and etiologies of liver disease were included, as well as VDD in the general population. The 
search was limited to English and Spanish language. 
Evidence  
VD and the Immune System  
Adaptive versus innate immunity. The role of VD in calcium regulation and bone 
homeostasis is well established (Holick et al., 2011; Lucey et al., 2013); however, recently VD 
has been recognized as possessing immunomodulatory, anti-inflammatory, and anti-fibrotic 
properties (Arteh, Narra, & Nair, 2010; Fernandez-Fernandez et al., 2015; Kitson & Roberts, 
2012).  Additionally, VD has a key function in the management of cell proliferation and 
differentiation, both extra-skeletal effects that are important in the pathogenesis and treatment of 
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various etiologies of liver disease (Kitson & Roberts, 2012). With respect to adaptive immunity, 
VD is an essential regulator of T cell response (up-regulation) to pathogens, and VDS is 
associated with a lower risk of various autoimmune diseases (Kitson & Roberts, 2012; Putz-
Bankuti et al., 2012). In orthotopic liver transplant (OLT) recipients, severe VDD has been 
associated with moderate to severe acute T-cell mediated rejection (ATCR) with VDS decreasing 
the incidence of ATCR by as much as 60% (Kitson & Roberts, 2012; Stein & Shane, 2011; 
Thiem et al., 2013). Reducing graft failure is a highly desirable outcome of VDS as ATCR can 
predispose a patient to steroid-resistant rejection and graft loss (Cotler, 2016). 
VDS has also been shown to increase the effectivity of the innate immune system, thus 
providing protection against bacterial infections and tuberculosis (Anty et al., 2014; Chowdhury 
et al., 2014; Putz-Bankuti et al., 2012; Stein & Shane, 2011; Zhang et al., 2016).  Notably, 
cirrhotic patients with severe VDD (<10ng/mL) were independently associated with bacterial 
infections compared to patients with higher VD levels (Anty et al., 2014; Zhang et al., 2016), and 
low VD prior to hospitalization was a significant predictor (p=0.001) of sepsis in the critically ill 
(Moromizato et al., 2014).  
Sustained virologic response.  Chronic hepatitis C infection is one of the main causes of 
liver disease and increases the risk of developing hepatocellular carcinoma (HCC) by 2-6% per 
year (Oliviera-Andrade et al., 2009). Recent in vitro studies have shown that VD acts as an 
antiviral agent that inhibits hepatitis C virus (HCV) production in a human hepatoma cell line 
(DiCarlo et al., 2015). In patients with HCV that underwent OLT with subsequent recurrent 
HCV, high rates of sustained virologic response (SVR) were noted in patients receiving VDS 
(Abu-Mouch, Fireman, Jarchovsky, Zeina, & Assy, 2011; Bitetto et al., 2011; Iruzubieta et al., 
2014).  
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Cancer. Another common theme found in the literature is the association of VDD and 
cancer development, namely colon, prostate, and breast cancer (Iruzubieta et al., 2014; Stein et 
al., 2009; Stokes et al., 2014; Villar et al., 2013). VDD is prevalent among cancer patients with 
one study showing 74% of breast cancer patients to be low in VD and VDS conferring a 15% 
decrease in mortality among lung cancer patients (Aguirre et al., 2016).  Relevant to liver disease 
is that hepatocellular and intrahepatic cholangiocarcinoma often develop in patients with 
cirrhosis and is inversely related to levels of VD (Stokes et al., 2013). VD has strong evidence 
that it promotes anti-apoptotic activity, as well as anti-inflammatory and anti-angiogenic 
properties that promote cell differentiation and inhibit cancer cell proliferation (Courbebaisse et 
al., 2014; Stokes et al., 2013).  
VD and Non-Alcoholic Fatty Liver Disease  
Non-alcoholic fatty liver disease (NAFLD) is one result of metabolic syndrome (Kitson 
& Roberts, 2012). It is a relatively benign condition, and one result of the obesity epidemic that 
involves some fat infiltration into the liver without inflammation (Chopra, 2016). With a 
prevalence of up to 30%, NAFLD is rapidly becoming the most common etiology of chronic 
liver disease in developed western countries (Eliades & Spyrou, 2015; Iruzubieta et al., 2014; 
Kitson & Roberts, 2012; Lim & Chalasani, 2012). Of the patients with NAFLD, 30% have 
histological evidence of non-alcoholic steatohepatitis (NASH), the complicated form of NAFLD, 
risking a high rate of disease progression to cirrhosis (Kitson & Roberts, 2012). Unfortunately, 
incidence of NAFLD is expected to rise along with the obesity epidemic (Eliades & Spyrou, 
2015). NAFLD is generally known to be associated with at least one metabolic syndrome 
characteristic, and insulin resistance (IR) has been discussed as a key factor in the development 
of NAFLD (Del Ben et al., 2014; Iruzubieta et al., 2014).   
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VD and Hepatic Osteodystrophy  
Bone loss associated with liver disease and related treatment is a major issue that is the 
subject of studies, reviews, and clinical practice guidelines. Also known as hepatic 
osteodystrophy (HO), this general term defines a group of derangements of bone mineral 
metabolism found in patients with CLD (Lopez-Larramona, Lucendo, Gonzalez-Castillo, & 
Tenias, 2011). Bone loss in this population can be severe enough to cause atraumatic fractures, 
leading to compromised mobility and subsequent decrease in quality of life (Nakchbandi, 2014). 
However, HO is multifactorial in origin and appears to be the consequence of metabolic bone 
disease making it impossible to process VD due to the interruption in liver function from disease 
(Choudhary et al., 2011; Nakchbandi, 2014; Lopez-Larramona, Lucendo, Gonzalez-Castillo, & 
Tenias, 2011).  
VD and Mortality in Liver Disease  
In 2013, CLD was ranked twelfth on the leading causes of death in the US and fifth in 
Europe (Xu, Murphy, Kochanek, & Bastian, 2016). VDD has been associated with higher 
mortality risk in the general population, and given the prevalence and degree of VDD, patients 
with CLD are extremely vulnerable to the consequences of VDD as well (Stokes et al., 2014). 
Furthermore, a large observational study conducted by the US National Health and Nutrition 
Examination Survey (NHANES) concluded that serum VD levels are inversely related to all-
cause mortality (Zhao, Ford, Li, & Croft, 2012). In a meta-analysis of 18 randomized controlled 
trials, Autier and Gandini (2007) concluded that VDS correlated with a reduction in overall 
mortality in the general population.  
Clinical Practice Guidelines on VDS  
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The American Association for the Study of Liver Diseases (AASLD) is the main expert 
body in the US for opinion in the field of liver disease, and providers in hepatology and related 
practice areas refer to AASLD for guidance on treatment for various liver-related issues. The 
AASLD, together with the American Society of Transplantation (AST), publishes clinical 
practice guidelines (CPG) for successful long-term management of the adult liver transplant 
recipient. In the guidelines, the benefit from VDS in the post transplanted patient are addressed 
and include improved sustained virologic response for patients with HCV, immune system 
fortification against both infection and graft rejection, and a decreased incidence of malignancies 
(Lucey et al., 2013). Moreover, guidelines from the AASLD, the AST, and the Endocrine 
Society recommended maintaining a minimum of 30ng/mL serum VD (Holick et al., 2011). 
Additionally, patients on steroids, anti-fungals, and certain antiviral medications used for 
prevention of hepatitis B recurrence are also at a higher risk for VDD and should be 
supplemented two to three times more than their age-group requires (Holick et al., 2011).  
The Case for VD Supplementation 
A recent resurgence of the benefits of VD on overall health of the general population 
contributed to a meta-analysis of 25 randomized, placebo-controlled trials evaluating the dose 
response relationship of oral vitamin D3 (Jarrett, Ducasa, Buller, & Berwick, 2014). A regression 
analysis of all reviewed studies showed a correlation of 61% which supported a consistent dose-
response relationship independent of various confounders (Jarrett et al., 2014). Additionally, the 
researchers found that healthy and ill individuals did not vary on response to dose, supporting a 
generalizable dosing schedule (Jarrett et al., 2014). In a meta-analysis of randomized controlled 
trials of oral vitamin D supplementation, it was found that high-dose VDS (> 800IU/day) was 
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more beneficial in the prevention of hip fracture and any nonvertebral fracture in people 65 years 
and older (Bischoff-Ferrari et al., 2012). 
Theory, Change Process 
The Diffusion of Innovations (DOI) theory is the most prominent example of classical 
change theory that describes the natural process of innovation adoption (Macdonald, Graham, & 
Grimshaw 2014). The DOI theory examines the application of proven interventions into daily 
practice and contends that the rate of innovation is attributed to characteristics of both the 
product and the people meant to adopt the product (Nilsen, 2015). The DOI theory has been used 
to introduce new information in a variety of areas such as nursing, medicine, marketing, and 
technology. In nursing, it has been used to examine the nurses’ role in vaccine uptake (Rosen & 
Goodman, 2014), implementing a pain medication protocol for nurses in the ED (Hadorn, 
Comte, Foucault, Marin, & Hugli, 2015), and AIDS/HIV prevention (Melkote, Moore, & Velu, 
2014). 
Theory Concepts 
The first concept, adoption, is the act of employing an innovation systematically and is a 
salient concept in the DOI process (Nilson, 2015). This DNP project is prescriptive in nature; 
therefore, success is contingent on evidence adoption by other providers in the liver transplant 
department, as well as patient compliance. Without adoption, evidence based practice (EBP) 
would remain an elusive concept confined to the dusty annals of nursing and medical journals. 
Communication is a fundamental concept facilitating leadership and teamwork which are the 
most important constructs for planned change (Mitchell, 2013). The DNP project must 
communicate the discrepancy in care that exists in addition to the negative impact that such a 
discrepancy has on the patient population. 
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Methods 
Institutional Review Board  
An IRB (Institutional Review Board) application was first filed at the University of 
California, Los Angeles. As a result of this process, UCLA did not feel review was required due 
to the nature of the study. An IRB was then filed with the University of Missouri, Kansas City 
who categorized the project as not human subjects research (see appendix I).  
Ethical Issues 
Informed consent was provided in English or Spanish, and subjects were given the 
opportunity to participate without coercion or decline. Patients that didn’t speak English as a 
primary language understood that they would receive the same treatment regardless of 
participation in the DNP project. Standard HIPAA regulations were observed. Potential conflicts 
of interest included SI bias when recruiting patients to participate. 
Funding 
Funding was projected to be minimal for this DNP project, as the intervention was a 
component of the existing plan of care. The 25-hydroxy vitamin D serum check was part of the 
standard lab draw and was expected to be covered by the patient’s insurance. The cost of the 
vitamin D3 pills was minimal for a 12-week supply, approximately $10, and covered the 
duration of the protocol. Vitamin D3 was also covered by some of the patients’ insurance, and 
others were able to pay out of pocket. The patients followed up at regularly scheduled 
appointments with their hepatologist or primary care provider, avoiding additional costs of a 
clinic or lab visit. For the project, the cost of the advance practice registered nurse (APRN) was 
$631.00. 
Setting and Subjects 
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The setting was a large academic tertiary facility located in a large metropolitan city on 
the west coast. This facility has one of the country’s largest liver transplant programs with 163 
patients receiving livers in 2014 ("US Liver Transplant Centers," 2016). Inclusion criteria were 
post transplanted less than six months with a serum 25(OH)D of less than 30ng/mL and the 
ability to understand and speak English or Spanish. Exclusion criteria were 25(OH)D greater 
than 30ng/mL, post-transplantation greater than three years, need of translator services in 
languages other than English or Spanish, and patients that are currently on Vitamin D 
supplements. Patients with a documented history of poor medication compliance were excluded. 
Convenience sampling was used and a total of 48 patients were included in the project. 
Evidence Based Practice Intervention  
Patients with liver disease are inherently at risk for severe VDD and the various 
comorbidities include compromised immune system function, metabolic disorders, and hepatic 
osteodystrophy (Courbebaisse et al., 2014; Thiem et al., 2013). Clinical practice guidelines 
endorse a minimal level of 30ng/mL for serum 25-hydroxy vitamin D for patients prior to and 
after liver transplantation (Holick et al., 2011; Kitson & Roberts, 2012). This DNP project 
proposed a VDS protocol with the intention of fulfilling clinical practice guideline 
recommendations. Clinical providers on the in-patient liver transplantation service were educated 
on the protocol by the SI; however, the SI identified all eligible subjects through a chart review. 
A newly admitted patient with pre or post-transplanted status had 25-hydroxy vitamin D drawn 
along with standard labs. If the patient was found to be lower than 30ng/mL, the protocol was 
initiated. Once the protocol was an established part of care, any provider who was caring for the 
patient could order it.  Long-term effects such as incidence of acute cellular graft rejection or 
fractures can be tracked and reviewed in future cohort studies. 
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Intervention steps. The DNP project started in June 2016 with the IRB application to 
UCLA Medical Center and UMKC. July 2016 was slated for candidate identification of post 
liver transplant; however, this was delayed due to availability of the renal service. Patient 
identification started in September 2016 and was accomplished via chart review of patients 
admitted at the time to the liver transplant service at UCLA Medical Center. The director of post 
transplant coordinators facilitated a weekly clinic schedule which allowed the SI to review which 
transplanted patients needed VDS. As eligible patients were identified weekly, informed consent 
occurred on a rolling basis and was acquired in person by the SI at the clinic or occasionally by 
telephone. The initiation of the protocol started September 2016; and all identified patients after 
that time started the new VD supplementation intervention ordered by SI. Recruitment continued 
until January 2017 at which point 47 patients were included. The SI tracked the 12-week time 
frame for each individual. The patients returned to clinic at their regularly scheduled 
appointment which was usually within 1-2 weeks of the 12 week treatment course. 
EBP Model, The Clinical Scholar Model  
The Clinical Scholar Model (CSM) was developed to promote thoughtful inquiry, 
educate direct care providers such as nurses and advance practice nurses (APRN), promote EBP 
mentorship, and conduct research in a clinical setting (Melnyk & Fineout-Overholt, 2015). The 
model can help identify problems in a setting, key stakeholders, and areas in need of 
improvement (Honess, Gallant, & Keane, 2009). It also provides a framework to examine both 
internal and external evidence (Honess et al., 2009). One of the goals of the CSM is to review 
current practices in direct care in favor of an intervention that has evidence to be beneficial 
(Melnyk & Fineout-Overholt, 2015; Honess et al., 2009). 
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With respect to the project, the CSM aligns well with the inquiry in this project which  
questions the current sporadic supplementation of vitamin D and seeks out guidelines that 
recommend a minimum serum level. Both internal evidence, which is the vitamin D levels prior 
to supplementation as well as serum levels after supplementation, and external evidence  
examined within the project.  The DNP project was presented to the liver transplant APRN 
colleagues as well as the staff nurses who care for these patients. The hope was that the example 
of challenging an existing practice with an evidence based intervention would encourage nurses 
on the unit to develop this same clinical inquiry for their own nursing practice. 
Study Design 
The non-randomized nature of this DNP project inherently makes this a quasi-
experimental study. Serum vitamin D levels were analyzed in the post-transplanted population. 
The patients started the vitamin D supplementation protocol during hospitalization, and VD 
levels were assessed at 12 weeks.  
Validity  
Internal validity. Internal validity for the DNP project was assessed by the laboratory’s 
approach to measuring serum 25-hydroxy vitamin D. Subjects for the study were selected 
through the convenience method and were assumed to be a representative sample of vitamin D 
deficient patients that are newly or recently transplanted within the last three years. The main 
threat to internal validity in this quasi-experimental study was the inability to determine a cause 
and effect relationship of the intervention (Kleinpell, 2013). However, inclusion criteria for this 
project were that the subject was vitamin D deficient (<30ng/mL). The patients were not on any 
other vitamin D supplementation, and as a result, the expected increases in post intervention lab 
values were attributed to the VDS intervention. 
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External validity. Despite the application of a vitamin D protocol to a specific 
population, the generalizability of implementing an intervention aimed at improving sub-optimal 
levels of VD is applicable to the general population. In a meta-analysis of randomized controlled 
studies, a strong dose-response was found between the amount of supplement and change in 
serum VD (Jarrett, Ducasa, Buller, & Berwick, 2014). Most important, these results did not 
change when the review limited the results to studies using healthy individuals (Jarrett et al., 
2014). Vitamin D insufficiency and deficiency are widespread in close to half the population of 
healthy individuals in industrialized countries (Iruzubieta, et al., 2014). In patients with chronic 
liver disease, this statistic increases up to 93% (Iruzubieta et al., 2014). The DNP project targeted 
liver disease; however, the dose response and benefits of optimized vitamin D is universal. 
Outcomes to be Measured  
The primary outcome was to assess the effectiveness of a vitamin D protocol on serum 
levels in newly transplanted patients. The baseline VD level was compared to the 12-week VD 
level. Secondary outcomes included evaluating the dose in the patients that were not successfully 
optimized to 30ng/mL. Patients with lower vitamin D levels may need a more aggressive 
supplementation protocol, rather than the homogeneous dosing schedule used in this project.   
Measurement Instrument    
 At the SI’s facility, the chemiluminescent immunoassay (CLIA) is the method of 
measurement. The CLIA method detects the concentration of vitamin D in a specimen through 
the quantification of luminescence resulting from chemical reactions (Wang, Wu, Zong, Xu, & 
Ju, 2012). Validation is performed only by CLIA-licensed facilities ("AACC," 2016). The 
advantage of the CLIA measurement is that it is highly sensitive with a good level of specificity 
(Wang et al., 2012). 
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Quality of Data  
        Power analysis was calculated given the amount of subjects included. Pre data was 
the patient’s 25-hydroxy vitamin D level. Post data was the repeat lab value of serum 25-hydroxy 
vitamin D after the 12-week supplementation protocol. The recent meta-analysis by Jarett et al. 
(2014) lists 25 studies in which subjects were supplemented with VD over various periods of 
time, and this review was used as a primary source for comparison with the current project 
results. A more recent randomized controlled trial by Pilz et al. (2016) also provides a reference 
for expected increase specifically in patients with cirrhosis. 
Analysis Plan  
    Demographics included age, race, and gender. For outcome data, there was an 
expectation that an increase in serum 25(OH)D would occur. Therefore, a one-tailed t-test was 
the statistical approach in analyzing the post lab and difference from the VD level prior to the 
VD supplementation protocol. A p-value of 0.05 was considered statistically significant 
(Gravetter & Wallnau, 2011) and was the minimal value to determine if the protocol was 
sufficient in optimizing vitamin D levels in post-transplanted patients. 
Results 
Setting and subjects 
The setting was a large academic tertiary hospital and the corresponding outpatient 
hepatology clinics in a large metropolitan city on the west coast. Subjects were post liver 
transplantation of three years or less with normal renal function (GFR >30) found to be VDD as 
defined by a serum 25-OH D level of less than 30ng/dL. Participant (n=45) ages ranged from 48-
70 years old and were Hispanic (50%), Caucasian (28%), African-American (11%), and Asian 
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(11%). The project racial breakdown mirrored the city’s racial demographic as reported in the 
2010 US census ("US Census," 2016).  The gender distribution was 51% male and 49% female.  
Intervention Course 
Eligible patients were identified using the inpatient census at the beginning of the project 
period in September 2016. These patients were approached and educated on the importance of 
vitamin D supplementation by the SI. If the patient was not currently taking vitamin D, 
cholecalciferol (vitamin D3) 2500IU/day was added to the medication list for a duration of 12 
weeks and the start date was noted in the SI’s database. To capture additional subjects, the SI 
approached the post transplant director who then facilitated a weekly outpatient hepatology clinic 
list with patient names and transplant dates. Approximately 60 patient charts were reviewed 
every week over the course of four months which resulted in over 900 charts reviewed for the 
time period. Additional patients were identified on a weekly basis until January 2017 and the SI 
attended clinic to verbally discuss the new supplement. After the 12-week course of 
cholecalciferol, patients returned to clinic for their regularly scheduled hepatology appointment 
and a vitamin D level was obtained. This result was compared to the pre-treatment vitamin D 
level.  
Outcome Data 
The primary outcome measure was the difference between the pre and post treatment 
serum levels of 25(OH)D. The project sample size was to represent at least a power of .8, 
medium effect, alpha .05 which was 30 patients. Recruitment continued until the 12-week 
treatment duration would place the patients re-draw date beyond March 2017. The first patients 
were captured in September 2016 with the last added in January 2017. With these criteria, a total 
of 48 was added. However, one patient’s Endocrinologist changed him to ergocalciferol (D2), 
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and two patients refused to pay the supplemental cost for the cholecalciferol (D3). Therefore, 
total subjects were 45.   
Statistical analysis. Before patient recruitment began, the SI met with statisticians and 
discussed an appropriate sample size. It was assumed that approximately 70% of the patients 
would respond to the dose indicated by Endocrinology as the expectation was that most patients 
would reach the minimum target level of 30 ng/mL as found in the meta-analysis by Jarrett, 
Ducasa, Buller & Berwick, 2014 and Pilz et al., 2016. Based on this expectation a power analysis 
was calculated to determine appropriate sample size that would give a confidence interval (CI) of 
>90%. Final data indicated that 35 of the 45 patients reached the minimum vitamin D serum 
level of 30 after VDS, or 78% of the subjects. This was a greater than expected response. 
Additionally, there was a mean change in serum VD level of 14 ng/mL, however, not all of the 
patients in the study reached the minimum level of 30 ng/mL.   
Additional analysis was performed on the following sub-categories of the study subjects: 
etiology of liver failure, race, and gender (appendix J). There were some significant differences 
in how these subcategories responded, namely, Asians had an average increase of over 80% post 
intervention. Females also appreciably improved post intervention at 81% while males had a 
62% change post intervention. There were no significant differences in improvement among the 
varying etiologies of liver failure. 
An estimate of the proportion of responders to the vitamin D intervention, along with a 
95% confidence interval, was reported. A one-sided one-proportion z-test was used to evaluate 
the null hypothesis that 50% or fewer will respond after the vitamin D intervention. A p-value 
less than 0.05 was considered statistically significant. The sample size of n=45 provides 94% 
power to detect a true proportion responding after the vitamin D intervention of 78% (p<0.001). 
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Missing data included the three patients that did not start the cholecalciferol supplementation 
either due to cost/access or prescription of ergocalciferol by another Endocrine physician.  
Discussion 
This DNP project raised awareness of the importance of vitamin D in this vulnerable 
population. Accordingly, co-workers and transplant coordinators were more vigilant with this lab 
value and benefits to VDS than prior to the project. The vitamin D supplementation protocol was 
shown to be an effective approach to optimizing serum levels and a large portion of the patients 
that were started on cholecalciferol reached the minimum dose as recommended by the 
guidelines.   
Study Strengths 
The project’s success relied heavily on the team approach to facilitating the protocol 
implementation. Although the SI was the sole person following the patients and their re-draw 
dates, at many points of time, the post transplant coordinators were contacted regarding details 
about the patients’ access to VD as well as their expected return to clinic. Additionally, the 
transplant pharmacist was exceedingly helpful and cooperative in sending the supplementation to 
patients’ homes in the event that were not expected back in clinic within 1-2 weeks. The 
organizational culture at the project site is supportive of quality improvement projects that can 
improve patient outcomes such as this DNP project.  
Because this facility was a large academic hospital, significant resources are available to 
facilitate this project. This is especially true for the post-transplanted population. These patients 
are each assigned a post-transplant coordinator that arranges all appointments as well as the 
contact person for any potential complications. Coworkers on the liver transplant service were 
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also communicative when questions arose regarding the study subjects’ VDS. This allowed for 
seamless continuance on patient supplementation without compromising the results.  
Comparing Results 
Comparing dose-response results with published literature was a challenge because there 
are limited studies dedicated to VDS in liver disease and post transplant. However, as Jarret et 
al., 2014 observed in their meta-analysis of 36 studies, the dose response of VDS did not vary in 
the absence of chronic disease. Both healthy and chronically ill populations that were analyzed 
responded well to VDS.  The results from this DNP project were compared to the meta-analysis 
by Jarrett et al. (2014) as well as a randomized controlled trial by Pilz et al (2016) examining 
vitamin D supplementation, specifically in cirrhotic patients.   
In their meta-analysis, Jarrett et al. (2014) plotted the data from 20 of the most reliable 
and homogeneous studies on a scatter plot which showed a positive correlation between the 
quantity of oral VD and the change in serum levels. Based on this information, a daily dose of 
D3 at 2500 units would produce a change in serum level of 16ng/mL. In the RCT of cirrhotic 
patients, Pilz et al. (2016) employed a daily dose of 2800 units/day and found a mean change 
from baseline post VDS of 18 ng/mL. The mean change among the DNP project’s subjects was 
14ng/mL with the 2500 unit daily dose which resembles the meta-analysis’ and the RCT 
findings. Although both studies discussed a minimum normal range of 30 ng/mL, the number of 
patients that reached that goal post VDS was only reported in ranges rather than in individual 
cases.  
Study Limitations  
There are several limitations that should be mentioned with respect to the results. This 
was a single-center observational study with a small sample size. There are no previous studies, 
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to the SI’s knowledge, that examine post transplant VDS supplementation and dose response. In 
newly transplanted patients, the exact effect of the functioning liver on the improvement of 
serum vitamin D is unclear. However, liver disease does not always impair vitamin D receptor 
function and hypovitaminosis D is thought to be a consequence of poor nutritional intake and 
sedentary lifestyle (Elangovan, Chahal, & Gunton, 2017).  
Serum vitamin D results take over 24 hours to process, therefore when a patient was 
identified as being deficient, oftentimes they were no longer on site to prescribe VDS. This 
occasionally caused a problem with respect to access to the vitamin because patients did not 
want to pay additional money out of pocket to buy VD and returning to clinic was not convenient 
until the next scheduled appointment. In some cases, the pharmacist was able to mail the vitamin 
to patient’s homes. Post intervention data collection at the indicated time became a major 
challenge in some cases also due to the patients’ return-to-clinic schedule not corresponding with 
the end of the 12-week period. This could potentially affect the post lab draw result if too much 
time elapses between last dose and next lab draw.  
Despite meticulous communication with Endocrine, at least 2 patients were started on the 
wrong form of vitamin D (ergocalciferol). Therefore, those patients were taken out of the study.  
Generalizability factors relevant to broader application of this study include the acuity of the 
transplanted population in the region of Southern California and the dose of VD recommended. 
Liver disease and post-transplanted patients may not need the same amount of VDS to achieve 
the minimum guidelines.   
Potential for the vitamin D protocol to become another casualty in the efforts to improve 
patient outcomes is significant. The liver transplant service is volume heavy with critically ill, 
complex patients and vitamin supplementation is not high on the list of priorities for care. This 
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project has raised awareness, and it became clear that despite being a benign intervention, the 
department stake holders were very cooperative and willing to work on incorporating this 
protocol into the workflow of both pre and post-transplanted patient care plans. Meetings with 
the post transplant coordinators were productive, and it was discussed that the outpatient 
hepatology clinic could be the responsible party for monitoring vitamin D and adjusting doses as 
needed with surveillance eventually transferring back to the patients’ primary care provider.  
Efforts to minimize limitations included constant communication with post transplant 
coordinators, coworkers involved in both inpatient and outpatient settings, and patients 
themselves. It was sometimes noted that when subjects were readmitted that their vitamin D was 
not started with the other home medications. This required re-education of the admitting 
provider. Patients were also reminded of the importance of compliance via telephone or in 
person. Coordinators were updated on re-draw plans and assisted with ordering labs for those 
patients that lived outside of the city where the study was carried out.  
The limitations affected the results: inability to get the medication to the patient in a 
timely manner, return to clinic did not always correspond with designated re-draw dates, and 
awareness, although much improved, was not 100%. Regardless, the quantifiable nature of this 
project supports VDS and the benefits the review of literature is said to provide.  
Interpretation 
For the majority of the study subjects, the serum VD level increased to the minimum 
recommended level as expected. Patients were also very open to prioritizing vitamin D during 
educational discussions on the benefits to taking this vitamin. Given the pill burden for a post 
transplant patient, asking the patient to take, yet another, daily supplement was significant. 
However, patients were generally very supportive and open to doing so if they felt it would 
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improve their outcomes. With respect to the intervention, there were no unexpected results, and 
those patients that did not take VD as discussed did not increase their serum VD level. However, 
one unexpected and notable finding was how closely the convenience sampling of the subjects 
reflected the racial demographics of the city in which the study was carried out.  
Unexpected problems included the challenge of getting the appropriate dose 
recommended from the pharmacy. Vitamin D typically comes in 1000, 2000, or 5000 IU size 
pills. Our Endocrine recommendation was 2500IU which was a barrier to getting the dose in the 
beginning of the project. However, due to the assistance and cooperation of the transplant 
pharmacist, special orders of the 5000IU pills were placed, and patient used their pill splitter for 
their daily dose. Additionally, not all local pharmacies carried the 5000IU pill. This limited 
distribution to when the patients were able to come back to UCLA. At this point, the SI met with 
the pharmacist to inquire about sending the VD to the patients houses to facilitate initiation. This 
worked well and facilitated the progression of the DNP project.  
Intervention Effectiveness 
This DNP project showed the effectiveness of increasing patients’ vitamin D serum level 
to recommended guidelines using a protocol of a daily dose of 2500IU/day for 12 weeks. If 
patients were compliant and took their VD, it was expected that they would reach the 30 ng/mL 
level regardless of their baseline prior to supplementation. It was noted that patients who were 
severely deficient (less than 20 ng/mL) had a greater increase in serum than those that were 
above 20 but less than 30 ng/mL. This is consistent with the literature that contends that patients 
who receive the greatest benefit from VDS are those that are severely deficient (Bischoff-Ferrari 
et al., 2012; Gillespie et al., 2012; Martineau et al., 2017). A VD protocol such as the one 
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employed in this DNP project (see appendix L) is simple and easy to use in any setting whether it 
be an outpatient clinic or an inpatient facility.  
Intervention Revision 
Salient needs on this DNP project included additional assistance with managing the 
different areas of the implementation and follow-up process. Additional phone calls to patients to 
follow-up on compliance would have been very helpful, as well as the manpower to review all 
patients coming to clinic in the weeks to come and their baseline VD level. Raising awareness as 
to the importance of a requesting behavior is key, and the more people are involved in this, the 
more effective the message becomes. Occasional emails with current articles extolling the 
benefits of VD were sent to the post transplant coordinators in an effort to support the continued 
vigilance on vitamin D in our patients. Additionally, inpatient providers were also updated. 
Based on the results of this study, an increase of the daily dose of vitamin D would be increased 
to 3000units/day. This would assure greater increase in serum levels and would also make access 
easier, as 1000 unit pills are prevalent in most pharmacies.  
Health system costs and impacts. The expected impact on this health system was that 
this protocol would be an easy and effective intervention to address a basic need that fulfilled 
relevant guidelines to the affected population. Vitamin D supplementation is integrated into 
public policy through fortified products such as milk and other dairy products (Holick, 2010). 
For liver disease and post transplanted patients a high pill burden and limited dietary choices can 
make appropriate vitamin D intake challenging and a protocol that is incorporated into the 
workflow of patient care was shown to be highly effective in achieving guideline recommended 
levels of VD.  
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Estimated costs (appendix A) were edited when the amount of patients involved in the 
project increased from 30 to 45. Additionally, the initial estimated hours of the SI was lower at 
10 than the end result of 20 hours. This impacted the final cost. All but three patients were able 
to access the vitamin D either through insurance coverage or their willingness to pay out of 
pocket. Despite solicitation from multiple sources, no funding was granted.  
Conclusion    
This simple, inexpensive intervention has the potential for a high yield on investment 
based on the evidence of the protective benefits of vitamin D supplementation in the liver failure 
and transplanted population. Some of the major effects of optimized VD levels post 
transplantation include the decreased incidence of acute cellular rejection, decreased rate of 
infection, and reduced incidence of fracture (Kitson & Roberts, 2012; Moromizato et al., 2014; 
Nakchbandi, 2014). Vitamin D supplementation using ergocalciferol was the current approach at 
project site among liver transplant providers. The move towards cholecalciferol was appropriate 
given the evidence that it has shown to improve serum levels more effectively than ergocalciferol 
(Logan et al., 2013; Mangoo-Karim et al., 2015; Osborn & Germann, 2011).  
Further Studies  
Given the limited time frame for which to evaluate the effects of long-term optimized 
VD, further studies will be needed to determine if the VDS and subsequent optimization of 
serum 25(OH)D can curtail the incidence of graft rejection, infection, fractures, and other 
consequences of VDD. Tracking fresh liver transplanted patients that are maintained with VDS 
and their incidence of graft failure in comparison, retrospectively, with patients who were noted 
to be consistently VDD is one example of how VDS can be confirmed as an essential component 
of treatment in this population.  
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The accumulated findings of this DNP project will be shared with the providers at the 
inpatient practice at the project site, as well as the patient’s hepatologist, liver transplant 
coordinators, registered dieticians, and healthcare providers.  Additionally, the project was 
presented at the annual California Association of Nurse Practitioner’s educational conference in 
San Francisco and the UMKC Health Sciences Student Research Summit in Kansas City, 
Missouri. Project dissemination will be essential in raising awareness and subsequently 
addressing vitamin D deficiency. It will also serve to provide education on the ease of 
incorporating a protocol for supplementation, hence, improving patient outcomes in the future.  
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Appendix A 
Project Cost-Analysis 
Cost Analysis 
Direct costs Unit cost Quantity Total 
Serum 25-hydroxy vitamin D post 
supplementation lab draw 
$30  45 
patients 
$1350 
Vitamin D3 supplement for 12 weeks $10 45 
patients 
$450 
Student investigator  $63.21/hr 20hrs $1264.20 
Total Program Cost   $3064.20  
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Appendix B  
 
Definition of Terms 
 
Cholecalciferol: also known as vitamin D3, this is an animal based compound (Mangoo-Karim et 
al., 2015). 
Clinical practice guidelines from the American Association for the Study of Liver Diseases, The 
American Transplant Society, and the Endocrine Society recommend levels of vitamin D are 
30ng/mL and above (Holick et al., 2011; Lucey et al., 2013) 
Ergocalciferol: also known as vitamin D2, this is a plant-based sterol (Mangoo-Karim et al., 
2015). 
Large academic hospital in this study: University of California, Los Angeles 
Vitamin D deficiency: serum 25(OH)D level of less than 20ng/mL (Drezner, 2016). 
Vitamin D insufficiency: serum 25(OH)D level of less than 30ng/mL (Drezner, 2016). 
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Appendix C: Review of Evidence Table   
First author, Year, 
Title, Journal 
Purpose Research Design1 , 
Evidence Level2  & 
Variables 
Sample & 
Sampling, Setting 
Measures & 
Reliability (if 
reported) 
Results & Analysis 
Used 
Limitations & 
Usefulness 
VDS & THE IMMUNE SYSTEM 
Zhang, C., 2016  
Enhanced LL-37 
expression 
following vitamin D 
supplementation in 
patients with 
cirrhosis and 
spontaneous 
bacterial peritonitis 
Liver International 
 
Further investigate 
hypothesis that 
innate 
immunodeficiency 
in peritoneal cavity 
caused by low VD 
leads to 
vulnerability to 
bacterial infections 
with unfavorable 
outcomes 
Quantitative, 
observational, 
cohort, Level IV 
Variables: LL-37 
expression, VD 
levels, presence of 
spontaneous 
bacterial peritonitis 
(SBP)  
 
N=119 patients with 
chronic liver disease 
(CLD) in a single 
center academic 
facility in China 
Lab values of serum 
vitamin d (25-OH-
VD), vitamin D 
receptor (VDL) and 
LL-37 in peritoneal 
leucocytes were 
detected and 
compared to those 
without SBP 
VDD was found in 
all cirrhotic patients. 
Low VD levels 
inhibit the LL-37 
response of 
peritoneal 
macrophages, thus 
making the patient 
more vulnerable to 
SBP. This can be 
remedied with 
vitamin D 
supplementation 
(VDS). Univariate 
analysis was used.  
Clinical 
significance: 
Supports VD 
supplementation 
Limitations: 
Authors did not 
highlight any, 
however single 
center studies are 
always considered a 
limitation, as it is 
not necessarily 
reflective of 
worldwide 
population. 
Geographic location 
in northern region 
has less sunlight, 
affects VD levels to 
higher degree 
 
DiCarlo, P. 2015, 
Vitamin D and 
osteoporosis in 
HIV/HCV 
coinfected patients: 
A literature review 
International 
Journal of 
Endocrinology 
Summarizes 
prevalence of VDD 
in HIV/HCV 
coinfected, 
association between 
VD and liver 
disease and 
discusses impact of 
inexpensive therapy 
on reducing liver 
fibrosis and 
improving sustained 
virologic response 
IRR level VII 
Variables: VD 
levels, severity of 
liver disease, 
virologic response 
to HCV treatment, 
bone mineral 
density,  
12 articles were 
included: 10 original 
studies, 1 meta-
analysis/SR, 1 
review manuscript. 
Of these: 5 were 
cross-sectional, 2 
prospective cohort, 
3 retrospective 
Serum VD levels VD supplementation 
can be considered 
an inexpensive 
therapeutic option to 
lower HCV-related 
fracture risk 
Clinical 
significance: 
Supports VD 
supplementation 
Limitations: no RCT 
to examine those 
with VD 
supplementation and 
those without 
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rate  
Fernández-
Fernández, N. 
2015, Vitamin D 
deficiency in 
chronic liver 
disease, clinical 
epidemiological 
analysis and report 
after vitamin d 
supplementation  
Gastroenterología 
y  Hepatología 
 
Discover the 
frequency of 
vitamin d deficiency 
in patients with 
chronic liver disease 
(CLD) and whether 
VD supplementation 
influences plasma 
levels and is 
associated with 
improved liver 
function 
Quantitative, 
observational, 
cohort, Level IV  
Variables: vitamin d 
supplementation and 
liver function 
(Child-Pugh, 
MELD) 
N=94 patients with 
CLD (45 of which 
had cirrhosis) in an 
academic facility in 
Leon, Spain 
Lab values of serum 
vitamin d (25-OH-
VD), platelet 
counts, and albumin 
levels 
94% of patients with 
significant 
improvement were 
seen in platelet and 
albumin levels (p 
<0.5) and functional 
status assessed by 
Child-Pugh scale (p 
<0.5) 
Clinical 
significance: 
Supports VD 
supplementation 
Limitations: 
Time of year: winter 
and less hours of 
sunlight may have 
affected results, 
long term follow-up 
on VD levels: how 
long can 
supplementation 
sustain therapeutic 
levels? Lacked 
resources to 
determine if level of 
fibrosis was 
associated with VD 
levels 
Anty, R., 2014, 
Low levels of 25-
hydroxy vitamin D 
are independently 
associated with the 
risk of bacterial 
infection in 
cirrhotic patients 
Clinical and 
Translational 
Gastroenterology  
Compare 
hospitalized 
cirrhotic patients’ 
serum levels of VD 
with infection to 
those without 
infection 
Quantitative, 
observational, 
prospective cohort 
study, level IV 
Variables: serum 
VD, presence of 
infection (UA, 
bacteremia, PNA, 
SBP, bone 
infection) 
N=88 patients with 
cirrhosis admitted in 
a single-center 
academic facility in 
Nice, France 
Serum VD, Child-
Pugh score, C-
reactive protein, 
ALT level 
More patients with 
severe VDD were 
infected (54 vs. 
29%, P=0.02) More 
infected patients had 
severe VDD 
compared to those 
not infected (71 vs. 
46%, P=0.019) 
Clinical 
significance: severe 
deficiency in 25-OH 
VD was a notable 
independent factor 
correlating with 
infection. Supports 
VDS. 
Limitations: Single-
center study, small 
patient pop’n 
Courbebaisse, M., 
2014 VITamin D 
supplementation in 
renAL transplant 
recipients 
(VITALE): a 
prospective, 
multicentre, 
Assess benefit and 
safety of high-dose 
VD in post renal 
transplant patients 
Quantitative, 
double-blind, 
placebo controlled, 
RCT level I 
(ongoing study) 
Variables: VD 
doses, serum VD. 
Evaluate the risks 
N=640 renal 
transplant recipients 
in a multi-center, 
carried out in 30 
different transplant 
centers in Paris, 
France. Recruitment 
is to end in 2016. 
Serum VD, lipid 
profile, LFT, PTH, 
bone mineral 
density (BMD), 
fasting blood sugar 
Previous study by 
same group showed 
that intensive VD is 
well tolerated in 
renal transplant 
recipients, using this 
information, a dose 
specific result from 
Clinical 
significance: 
Potential to be a 
hallmark study 
given the duration 
(over 2 years) and 
quality of study. It is 
understood that 
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double-blind, 
randomized trial of 
vitamin D 
estimating the 
benefit and safety 
of vitamin D3 
treatment at a dose 
of 100,000 UI 
compared with a 
dose of 12,000 UI 
in renal transplant 
recipients: study 
protocol for a 
double-blind, 
randomized, 
controlled trial. 
Trials 
and benefits of high 
dose versus low 
dose VD, with 
endpoints of de 
novo DM, CV, bone 
fracture, or death 
the VITALE study 
is expected, with 
additional 
information on 
development of  de 
novo DM, CV, bone 
fracture, or death 
VDS is beneficial, 
however, more 
specifics on dose 
additional reported 
benefits are 
expected to be 
discovered as a 
result. 
Villar, MV., 2013, 
Association 
between vitamin D 
and hepatitis C 
virus infection: A 
meta-analysis 
Evaluation of the 
association between 
25-hydroxy-D and 
SVR in HCV 
infected patients 
IRR, level VII 
Variables: SVR, VD 
levels 
Inclusion of 11 
studies (eight 
observational and 
three interventional) 
with a total of 
n=1575 conducted 
by an academic 
facility in Brazil 
VD serum 
measurements using 
radioimmunoassays 
and 
chemiluminescence. 
Viral load of HVC 
infection regardless 
of genotype 
High rates of SVR 
were observed in 
HCV patients with 
VD >30ng/mL (OR 
1.57; CI 95%) and 
those supplemented 
with VD (OR=4.59; 
95% CI) of any 
genotypes 
Clinical 
significance: higher 
SVR for those with 
higher VD levels or 
receiving 
supplementation. 
Supports VD 
supplementation. 
Limitations: some 
studies were small 
pop’n, lack of VD 
assessment in 
control and 
treatment groups, 
one study was not 
placebo controlled 
Bitetto, D., (2011) 
Vitamin D 
supplementation 
improves response 
to antiviral 
treatment for 
recurrent hepatitis 
Examine influence 
of vitamin D 
serum levels and/or 
vitamin D 
supplementation 
with respect to 
systemic virologic 
Quantitative 
observational, 
cohort study. Level 
IV 
Variables: HCV 
quantitative serum, 
recurrence of SVR, 
N=89 consecutive 
patients who 
underwent liver 
transplantation for 
HCV-related liver 
disease at a single 
academic center in 
End of treatment 
viral response 
(undetectable level 
of HCV). Serum 
VD 
Vitamin D status at 
the when patients 
started antiviral 
therapy was related 
to the SVR after 
treatment of 
recurrent HCV 
Clinical 
significance: 
Supports VDS 
Limitations: Study 
design, retrospective 
study does not allow 
for complete control 
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C. Transplant 
International 
response (SVR) 
rates for 
recurrent hepatitis C 
(RHC) 
 
VD levels Italy Analyzing time to 
onset, evaluation of 
the relationship 
between vitamin D 
supplementation and 
resolution of HCV 
RNA and evidence 
of SVR was 
investigated 
 
 
of confounding 
variables 
VDS & Non-Alcoholic Fatty Liver Disease 
Eliades, M., 2015, 
Vitamin D: A new 
player in non-
alcoholic fatty liver 
disease? World 
Journal of 
Gastroenterology 
Examine the role of 
VDD in  the 
development of 
NAFLD, review 
evidence that 
connects VDD and 
NAFLD 
demonstrate value 
of VDS 
IRR, level VII 
Variables: VD 
levels, hepatic 
fibrosis, intestinal 
microbiome, insulin 
resistance 
Not specified Not specified Evidence shows that 
VD could be useful 
in preventing the 
progression of 
NAFLD through 
various pathways 
such as anti-
inflammatory and 
metabolic routes. 
Clinical 
significance: 
supports VD 
supplementation 
Limitations: few 
prospective 
randomized studies 
examining of VD 
supplementation in 
NAFLD 
Sharifi, N., (2014) 
Does vitamin D 
improve liver 
enzymes, oxidative 
stress, and 
inflammatory 
biomarkers in 
adults with non-
alcoholic fatty liver 
disease? A 
randomized clinical 
trial. Endocrine 
Determine the effect 
of VDS on serum 
liver enzymes, 
insulin resistance, 
oxidative stress, and 
inflammatory 
markers in NAFLD 
Quantitative, 
experimental, RCT, 
double-blind, 
placebo controlled 
Level II 
Variables: VD 
levels, VDS, hs-
CRP, MDA, LFT, 
HOMA-IR 
N=53 patients with 
NAFLD, randomly 
allocated to receive 
VD or placebo 
every 2 wks for 4 
mos in a single 
academic center in 
Iran 
Wt, waist 
circumference, waist 
to hip ratio, BMI, 
dietary intake of 
VD, physical 
activity, ultrasound 
Lab results of VD 
levels, VDS, hs-
CRP, MDA, LFT, 
HOMA-IR, US 
Clinical 
significance: 
supports VDS, 
shows benefit of VD 
in NAFLD and 
arresting 
progression to 
NASH 
Limitations: single-
center study, smaller 
study size. US is not 
as diagnostic as 
liver biopsy for 
degree of steatosis 
Iruzubieta, P., 
2014, Vitamin D 
deficiency in 
Functions of VD 
involved in 
development of 
Integrative review 
of research 
addressing VDD 
Review of 23 
articles (19 cohort, 
and 4 randomized 
SVR, VD levels, 
HCV genotype, 
histology of liver 
VD has pleiotropic 
effects that indicate 
a link between VDD 
Clinical 
significance: VDS 
may improve 
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chronic liver 
disease World 
Journal of 
Hepatology 
chronic liver disease 
(CLD) and 
relationship between 
VDD and two main 
causes of CLD: Hep 
C  (HCV) and 
NAFLD 
and  
supplementation in 
HCV cirrhosis and 
NAFLD. Level VII 
Variables: type of 
liver disease, VD 
levels and VDS, 
sustained virologic 
response (SVR) in 
HCV 
prospective cohort 
studies) conducted 
by an academic 
facility in Spain. 
and various chronic 
diseases (DM, 
CVD, AI, ID, 
several cancers and 
chronic disease). 
VD has been linked 
to increase risk of 
portal hypertension, 
mortality and worse 
histology in HCV 
and NAFLD.  
complications listed 
from VDD as well 
as SVR after HCV 
treatment. 
Limitations: 
prospective 
randomized, placebo 
controlled studies 
are need to complete 
review 
Vaidya, A., (2012)  
The independent 
association between 
25-hydroxyvitamin 
D and adiponectin 
and its relation with 
BMI in two large 
cohorts: the NHS 
and the HPFS. 
Obesity 
Evaluate the 
correlation 
between VD and 
adiponectin in large 
female cohort from 
the Nurses’ 
Health Study I 
(NHS) and men 
from the Health 
Professional’s 
Follow-Up Study 
(HPFS) 
 
Quantitative, 
observational, in 
two large cohort 
studies 
Level IV 
Variables: VD and 
adiponectin levels, 
BMI 
n=1206 for NHS 
n=439 for HPFS 
Multivariable linear 
regression  
analyzed the 
independent link 
between 25(OH)D 
and adiponectin 
after adjusting for 
variables that would 
affect results 
 
25(OH)D 
concentrations were 
correlated with high 
levels of  
adiponectin; 
independently 
related to 
adiponectin 
considering 
multivariable 
adjustments in both 
groups 
women:  
β=0.06, P<0.001;  
men: β=0.07, 
P<0.05 
 
Clinical 
significance: 
supports VDS,  
reduced levels of 
25(OH)D and 
adiponectin 
correlate with higher 
cardio and 
metabolic risk, 
evaluation of the 
effect of VDS on 
adiponectin is 
indicated 
Limitations: Cross-
sectional study 
design cannot 
confirm causality, 
but findings were 
consistent with 
similar studies 
Liangpunskal, S., 
(2011) Serum 
vitamin D 
concentrations and 
unexplained 
elevation in ALT 
among US adults. 
Digestive Diseases 
and Sciences 
Analyze the 
association 
between serum 
vitamin D levels and 
elevated ALT of 
unknown etiology 
using the data from 
NHANESIII   
 
Quantitative 
observational 
retrospective cohort 
study of 
NHANESIII 
conducted from 
1988-1994 
Variables: fasting 
glucose, LFTs, VD 
n= 308 
unexplained ALT 
elevation 
N=979 controls 
with normal VD 
VD concentrations 
divided into fourths 
based on  
distribution and 
association was 
examined by 
multivariate 
logistic regression 
analysis   
Participants with 
elevated ALT of 
unknown etiology 
had lower VD levels  
when compared 
to control group 
(61.8± 26.0 nmol/l 
vs. 66.8± 27.1 
nmol/l,P<0.01) 
Clinical 
significance: 
Negative correlation 
between elevated 
ALT and VD levels. 
Supports VDS 
Limitations: cross 
sectional design of 
the data does not 
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levels  
 
 show cause and 
effect relationship 
between serum 
vitamin D and 
unclear reason for 
elevation in ALT, 
results are from one 
measurement of 
serum vitamin D 
 
 
Von Hurst, P., 
(2010)  Vitamin D 
supplementation 
reduces insulin 
resistance in South 
Asian women living 
in New Zealand 
who are insulin 
resistant and 
vitamin D deficient: 
a randomized, 
placebo-controlled 
trial The British 
Journal of 
Nutrition 
Examine the effect 
of optimized VD on 
markers of insulin 
resistance in South 
Asian 
women who were 
insulin resistant and 
VDD 
 
Quantitative, 
randomized, double-
blinded, placebo-
controlled trial.  
Level II 
Variables: IR, VD 
levels, VDS 
N=81 south Asian 
women with IR and 
VDD ages 23-68 
residing in New 
Zealand 
Serum D levels, IR Notable 
improvements were 
observed in insulin 
sensitivity and 
resistance with VDS 
(P=0·003 and 0·02, 
respectively) IR 
most improved with 
VD of >80ng/mL. 
Lipid profile and hs-
CRP were not 
affected by VDS 
 
Improving VD 
status in IR women 
showed an 
improvment IR and 
sensitivity; insulin 
secretion 
unchanged. Ideal 
VD for reducing IR 
were shown to be 80 
– 119 nmol/l, 
supports VDS. 
Limitations: 
compliance with 
regimen was lower 
after 3 mos, sun 
exposure may have 
affected VD levels 
versus PO VDS 
 
VDS & Hepatic Osteodystrophy 
Chaney, A., 2015, 
Effectiveness and 
outcomes of current 
practice in treating 
VDD in patients 
listed for liver 
transplantation 
Endocrine Practice 
Determine the 
effectiveness of one 
single-center’s 
practice in 
addressing VDD in 
patients awaiting 
liver transplantation 
(LT) 
Retrospective cohort 
study; 
Level IV 
Variables: MELD 
score, VD levels, 
bone mineral 
density (BMD), 
immunosuppression, 
N=127 patients 
awaiting liver 
transplant in a 
single-center in 
Florida. Average 
MELD score=23 
(lower value) 
Serum VD levels, 
BMD via T-scores. 
No reliability 
reported 
84% of patients had 
VDD. Only 62% 
received VD 
supplementation  
pre-LT. VDD 
improved with 
supplementation, no 
association found 
Clinical 
significance: 
highlights lack of 
systematic 
supplementation.   
Limitations: 
Authors recognized 
their population’s 
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PTH level, BMI between VDD at 
LT, functional 
status, fractures, or 
readmissions post-
LT.  
liver disease was not 
as advanced and 
therefore can 
maintain better VD 
levels at this point.  
Single center study. 
Nakchbandi, I., 
2014, Osteoporosis 
and fractures in 
liver disease: 
Relevance, 
pathogenesis, and 
therapeutic 
implications World 
Journal of 
Gastroenterology 
Review discussing 
the relevance of 
bone loss in liver 
disease along with 
the evidence 
available describing 
the pathogenesis, 
diagnostic steps, and 
therapeutic options 
IRR, level VII 
Variables: VD 
levels, fibronectin, 
insulin-like growth 
factor 1, various 
cytokines, 
corticosteroids 
Literature review, 
studies not specified 
however 
bibliography 
numbered 137 
manuscripts 
Serum vitamin D 
levels 
Liver disease is 
associated with 
compromises in 
bone health with a 
corresponding 
association of 
fracture risk in this 
population. A 
minimum of VD 
and calcium 
supplementation is 
recommended 
Clinical 
significance: 
Supports VDS, 
reports an associated 
risk of fracture in 
liver failure.  
Limitations: focuses 
on the 
pathophysiology 
with limited actual 
studies supporting 
the theoretical 
disease process of 
bone loss and results 
of supplementation 
Krol, C., 2014, 
Longitudinal 
changes in BMD 
and fracture risk in 
orthotopic liver 
transplant 
recipients not using 
bone-modifying 
treatment 
Journal of Bone 
and Mineral 
Research 
Evaluate changes in 
BMD post OLT in 
liver transplanted 
patients not treated 
with antiresorptive 
agent to ID aspects 
of risk for loss of 
bone post OLT and 
study impact of 
changes in BMD on 
risk for fracture 
Quantitative, 
observational, 
cohort, level IV 
Variables: OLT and 
BMD in femoral 
neck and vertebral 
and resulting or 
absence of fracture 
post transplantation 
N=201 patients post 
OLT in a single 
center academic 
facility in The 
Netherlands 
Changes in BMD 
via T-scores on 
DEXA scans 
Significant 
relationship between 
age (>52y/o in 
women) OR 0.89, 
95%CI and use of 
calcineurin 
inhibitors (CNI) for 
immunosuppression 
(IS) (OR 0.95;95% 
CI) VDD did not 
indicate bone loss 
either at lumbar 
spine (p=0.080) or 
femoral  neck 
(p=0.674) Of risk 
factors evaluated, 
male gender (OR 
5.15 95% CI) and 
age ( OR 1.06; 95% 
Clinical 
significance: After 
OLT, reversal of 
cholestasis, VDD, 
and hypogonadism, 
which results from 
improved liver 
function, likely 
contributes to 
improvement in LS 
BMD 
Limitations: lacked 
treatment protocol 
for IS therapy, 
excluded patients 
with bisphosphonate 
treatment not 
allowing for 
comparison of 
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CI) were assc 
w/increased risk of 
fracture 
effects of 
treatments. Single 
center study. 
Dasarathy, D., 
2014 
Treatment to 
improve nutrition 
and functional 
capacity evaluation 
in liver transplant 
candidates Current 
Treatment Options 
in 
Gastroenterology 
Review of literature 
on Impact of 
malnutrition on liver 
transplant 
candidates 
Integrative review 
of research, opinion 
statement, levels V 
and VII 
respectively. 
Variables: VDD, 
muscle mass, 
presence of 
sarcopenia, amino 
acid 
supplementation, 
micronutrient 
replacement 
Not specified Not specified The data on VDS in 
improving outcomes 
could be stronger, 
however the 
material on 
poor outcomes in 
cirrhosis to VDD is 
credible. Replacing 
VD in cirrhotics 
should be standard 
of care in this 
population 
Clinical 
significance: 
sarcopenia is an 
important 
complication of 
cirrhosis. One 
component that can 
help is VDS 
Limitations: lower 
level of evidence, 
but overall 
consistent with 
general consensus 
on VDS 
Lucey, MR., 2013, 
Long-term 
management of the 
successful adult 
liver transplant: 
2012 Practice 
Guideline by the 
American 
Association for the 
Study of Liver 
Diseases and the 
American Society 
of Transplantation 
Clinical practice 
guidelines intended 
for providers 
treating adult liver 
transplanted patients 
suggesting select 
methods to 
diagnostic, 
therapeutic, and 
preventative facets 
of care 
Clinical Practice 
Guideline by two 
expert 
organizations. Level 
VII 
Guidelines based 
on: formal review 
and analysis of 
literature, a manual 
for assessing and 
designing practice 
guidelines, guideline 
policies, and the 
experience of the 
authors on the topic 
VD serum levels, T-
score values 
Osteopenic LT 
recipients should 
perform regular 
weight-bearing 
exercises and 
receive calcium and 
VDS (grade 1, level 
A) 
Clinical 
significance: 
supports VDS post 
OLT, something 
that could be carried 
on from pre-OLT 
status. 
 
Holick, M., (2011)  
Evaluation, 
Treatment, and 
Prevention of 
Vitamin D 
Deficiency: an 
Endocrine Society 
Clinical Practice 
Guideline The 
Journal of 
Clinical guidelines 
for the evaluation, 
treatment, and 
prevention of VDD 
focusing on the care 
of patients who are 
at risk for deficiency     
 
Clinical practice 
guidelines by expert 
organization. Level 
VII 
Guidelines based 
on: systematic 
reviews of evidence 
and communication, 
discussion between 
members of the 
Endocrine Society 
VD serum levels Patients at risk for 
deficiency, such as 
CLD, should have a 
reliable VD level 
drawn and 
supplement if 
needed.  
Clinical 
significance: 
supports VDS in 
high risk 
populations, 
including CLD, and 
post OLT due to 
nature of 
medications.  
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Endocrinology and 
Metabolism 
 
VDS & Mortality 
Stokes, C., 2014, 
Vitamin D 
deficiency is 
associated with 
mortality in patients 
with advanced liver 
cirrhosis  
European Journal 
of Clinical 
Investigation 
Prospective exam of 
vitamin D levels in 
a cohort of adv. 
Liver cirrhosis, 
followed up for all-
cause mortality 
Quantitative, 
observational, 
prospective cohort, 
level IV 
Variables: vitamin d 
level, MELD, 
Child-Pugh scores,  
N=65 patients with 
cirrhosis in a single-
center academic 
facility in Germany 
 Serum 25-
hydroxyvitamin D 
concentrations  
High correlation 
between mortality 
and vitamin d levels 
in cirrhosis, 48% 
died over course of 
study. ROC analysis 
showed vitamin d 
level of 6ng/mL as 
minimum between 
survivors and non-
survivors.  Kaplan-
Meier analysis of 
survival proved low 
vitamin d levels as  
predictor of death 
(OR=6.3, 95% CI, 
p=0.012) 
Clinical 
significance: low 
vitamin d in pre-
transplanted 
cirrhosis is a 
significant predictor 
of mortality. 
Supports VD 
supplementation. 
Limitations: single 
center study 
Trépo, E., 2013, 
Marked 25-
hydroxyvitamin D 
deficiency is 
associated with 
poor prognosis in 
patients with 
alcoholic liver 
disease Journal of 
Hepatology 
Investigate the 
association of VDD 
with histological 
damage, portal 
hypertension, liver 
function, and 
mortality in 
alcoholic liver 
disease (ALD) 
Quantitative, 
prospective case-
control cohort study. 
Level IV 
Variables: serum 
VD levels in ALD 
patients and healthy 
controls, Child-
Pugh scores 
N=525 (n=324 
caucasian ALD, 
n=201 healthy 
controls) at an 
academic facility in 
Belgium 
Serum VD levels, 
peripheral blood 
mononuclear cells 
(PBMCs), tumor 
necrosis factor-
alpha production 
Low VD levels are 
associated with 
increased liver 
damage and 
mortality in ALD 
using univariate and 
multivariable 
logistic regression. 
Patient survival 
estimated by the 
Kalan-Meier 
method. Statistical 
analyses were 
performed using 
SPSS 19.0 software 
Clinical 
significance: 
Data suggests that 
VDS could improve 
deleterious effects 
of pro-inflammatory 
cytokines in ALD. 
Supports 
supplementation 
Thiem, U., 2013, 
Calcidiol deficiency 
in end-stage organ 
Review clarifying 
and summarizing 
exisiting data on the 
Integrative Review 
of Research (IRR) 
of all solid organ 
Inclusion of eight 
studies (one RCT, 
three retrospective 
VD serum 
measurements, % of 
patients on VDS 
Patients with liver 
failure are high risk 
for VDD. 
Clinical 
significance: 
treatment with VDS 
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failure and after 
solid organ 
transplantation: 
status quo 
Nutrients 
average VDD in 
patients with organ 
failure and 
recipients of solid 
organ transplants. 
Also discusses 
interventional 
studies and clinical 
practice guidelines  
transplantation 
systems and the 
effect of VD. Level 
VII 
Variables for OLT: 
VD levels, presence 
VD supplementation 
cohorts, three 
prospective cohorts 
and one cross-
sectional study) 
conducted by an 
academic facility in 
Austria 
Supplementation is 
recommended by 
the Endocrine 
Society, the 
American 
Association for the 
study of liver 
disease, and the 
American Society of 
Transplantation 
is recommended, 
especially in 
osteopenic liver 
transplant recipients 
with a Level of 
Evidence A. 
Limitations: Only 
one RCT 
represented. 
Stokes, CS., 2013 
Vitamin D in 
chronic liver 
disease Liver 
International 
Discusses the 
epidemiological and 
functional 
relationships 
between VDD and 
CLD, as well as 
implications for 
therapeutic 
interventions 
IRR, level VII 
Variables: serum 
level of VD, VDS, 
hepatic 
osteodystrophy 
Inclusion of 15 
studies evaluating 
the impact of VDS 
Serum VD levels, 
BMD 
VDD extremely 
common in CLD 
and inversely 
correlated with 
disease severity. 
Evidence is 
emerging in support 
of positive impact of 
VDS in SVR, and 
deceased acute 
cellular rejection 
post OLT 
Clinical 
significance: 
Supports VDS, 
especially prior to 
OLT, as this may 
decease incidence of 
ATCR post OLT 
Limitations: most of 
the studies reviewed 
are cross-sectional, 
sample sizes tended 
to be smaller 
Zhao, G., (2012)  
Serum 25-
hydroxvitamin D 
levels and all-cause 
and cardiovascular 
disease mortality 
among US adults 
with hypertension: 
The NHANES 
linked mortality 
study. 
Whether 
concentrations of 
VD are inversely 
correlated with 
mortality risk 
among American 
adults with 
hypertension 
Quantitative, 
retrospective cohort 
study 
Variables: VD, 
hypertension, all-
cause mortality 
N=2609 subjects 
with hypertension 
Data from the 2001-
2004 National 
Health and Nutrition 
Examination Survey 
with mortality data 
obtained through 
2006 
Serum VD levels, 
presence of 
hypertension 
Concentrations of 
VD as a continuous 
variable were 
linearly and 
inversely associated 
with the risk of 
mortality from all 
causes (P= 
0.012) and from 
CVD (P=0.010) 
 
Clinical 
significance: 
although this study 
focuses on CVD 
population, it is 
telling with an all-
cause mortality 
result 
 
Autier, P., (2007)  
Vitamin D 
supplementation 
and total 
mortality: A meta-
analysis of 
Examine the risk of 
dying from any 
cause in subjects 
who participated in 
randomized trials 
testing the impact of 
VDS (ergocalciferol 
Meta-analysis of 
RCTs  
Level I 
Variables: VD 
levels, VDS, any 
health condition 
18 independent 
RCTs up to 2006 
with a total of 
N=57,311 
Serum VD levels, 
deaths from any 
cause, dose of VDS 
Intake of ordinary 
doses of vitamin D 
supplements seems 
to be associated 
with decreases in 
total mortality rates. 
The relationship 
Clinical 
significance: general 
support that VDS is 
beneficial to 
population. 
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randomized 
controlled trials 
Archives of 
Internal 
Medicine 
[vitamin D(2)] or 
cholecalciferol 
[vitamin D(3)]) on 
any health condition 
between baseline 
VD status, dose of 
VDS, and total 
mortality rates 
remains to be 
investigated. 
VDS and Serum Response 
Jarett, F. et al., 
(2014) 
The effective of 
oral 
supplementation 
of vitamin D3 on 
serum levels of 
vitamin D: A 
review. 
Epidemiology 
Examines the 
effect of vitamin 
D3 (dose-response) 
supplementation on 
serum level in 25 
RCTs 
Meta-analysis of 
RCTs  
Level I 
Variables: VD3 
dosing, serum level 
response in health 
and ill individuals 
25 RCTs 
examining VDS, 
16 studies with 
healthy cohorts, 9 
studies with 
disease and VDD 
Serum VD levels, 
dose of VDS.  
Positive correlation 
between amount of 
VDS and serum 
VD.  p-
value<0.001 and an 
r2 of 0.61. 
 
Clinical 
significance: 
Supports VDS as a 
means to increase 
serum VD levels in 
both healthy and 
diseased populations 
Pilz, S., Putz-
Bankuti, C., 
Gaksch, M., 
Spindelboeck, W., 
Haselberger, M., 
Rainer, F., ... 
Stauber, R. (2016). 
Effects of vitamin D 
supplementation on 
serum 25-
hydroxyvitamin D 
concentrations in 
cirrhotic patients: A 
randomized 
controlled trial. 
Nutrients, 8(278), 
1-10 
Examine the effect 
of VDS on patients 
with cirrhosis 
subsequently 
evaluating the 
changes in liver 
function and 
synthesis as a result 
of optimized 
vitamin D.  
RCT: double blind, 
double center, 
placebo-controlled, 
parallel-group study 
Level II 
Variables: serum VD, 
liver function tests, 
international 
normalized ratio 
(INR), bilirubin 
N=36 consecutive 
patients with 
cirrhosis 
randomized in to 
two groups, one 
received VD3 the 
control group, 
placebo, in two 
different academic 
centers in Austria 
Serum VD levels, 
bilirubin, INR, LFT 
Positive treatment 
effect as shown by 
increase in serum 
VD levels in 
cirrhotic patients, 
no changes 
between 
intervention and 
control group with 
respect to liver 
function  
Clinical 
significance: 
Supports VDS as 
primary goal to 
increase serum VD 
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Appendix D: Theory to Application Diagram   
 
 
The Diffusion of Innovation Theory as applied to the DNP project: 
 
Communication with 
Colleagues/PCP 
Past practice included 
sporadic 
supplementation, poor 
vitamin D levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Knowledge Persuasion Decision Implementation Confirmation 
Work culture at DNP 
site is open to EBP 
changes that support 
positive outcomes 
Perceived 
advantage by 
providers: 
benefit to the 
patient w/liver 
disease and post 
transplantation. 
Ease of use, 
limited side 
effects, low 
cost, supports 
goal of  EBP 
Uses 
protocol 
Forgets to 
check 
vitamin D 
and use 
protocol 
Eventual/continued 
use over time 
Fails to become 
part of standard 
of care 
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Appendix E: Logic Model for DNP Project  
 
  
Inputs 
 Intervention(s)                        Outputs  Outcomes -- Impact 
 Activities Participation  Short Medium Long 
Evidence, sub-topics 
• Vitamin D 
supplementation 
(VDS) and the 
immune system 
• VDS and Non-
alcoholic fatty 
liver disease 
(NAFLD) 
• VDS and bone 
health 
• VDS and 
mortality 
• Clinical practice 
guidelines 
Major Facilitators or 
Contributors 
-DNP student 
-DNP Advisor 
-Inpatient nutritionist 
-Endocrine and Renal 
physicians 
-Outpatient nutritionist 
-Hepatologists 
-Fellow inpatient APRNs 
-Outpatient transplant 
coordinators  
Major Barriers or 
Challenges 
-Knowledge deficits of 
providers 
-Patient compliance 
 EBP intervention which 
is supported by the 
evidence in the Input 
column  
 
Improving serum vitamin 
D to clinical practice 
guidelines in liver disease 
to reduce impact of 
comorbidities in this 
population 
 
 
Major steps of the 
intervention   
-Identification of patients 
that are severely deficient 
in vitamin D 
 
-Educate fellow providers 
on importance of VDS 
 
-Educate patients on the 
importance of compliance 
 
-Prescribe VDS protocol 
 
-Serial serum vitamin D 
checks over three months 
(monthly) 
The subjects  
Patients with chronic liver 
disease listed for 
transplantation 
Site 
UCLA Medical Center 
 
Time Frame  
July 2016: start inpatient 
provider education on VDS 
with presentation of DNP 
project, contact outpatient 
hepatologists at UCLA  
-Identify intervention 
subjects via chart review 
August: Contact patients to 
educate on study, get consent 
September: Start VDS on 
subjects with monthly 
checks through November 
December 2016: Collect 
data, analyze 
 
Consent Needed or other 
-IRB approval 
-Patient’s consent 
 
Person(s) collecting data 
-Author of the DNP project 
-Nutritionist in clinic 
 
Others: PCP, Hepatology 
 (Completed as student)  
 
Outcome(s) to be 
measured with valid & 
reliable tool(s)  
 
-Serum vitamin D levels 
post VDS 
 
 
 
 
 
 
Statistical analysis to be 
used 
• One tailed t-test  
(after student DNP)  
 
Outcomes to be measured  
 
-Maintenance of vitamin D 
levels post VDS 
 
 
 
 
 
 
 
 
 
 
(after student DNP) 
 
Outcomes that are 
potentials  
 
-Incidence of bacterial 
infections 
 
-Incidence of acute 
cellular rejection in 
transplanted patients 
 
-Insulin needs in diabetic 
patients  
Adapted from Rogers (2003) DOI 
diagram 
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Appendix F: DNP Project Timeline for vitamin D Supplementation in Liver Disease  
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Appendix G: Intervention Flow Diagram  
  
Patient 
identification and 
recruitment
•Assess patient 
for eligibility: 
pre OLT(n=15), 
or post <6mos 
(n=15)
Consent of study 
participants
•Consent of 
eligible patients 
with serum 
25(OH)D 
<30ng/mL  
Obtain baseline 
25(OH)D
•Recent 
25(OH)D level 
within last 
month
Start vitamin D 
supplementation 
protocol
•12 weeks of 
vitamin D3 
daily (2500IU)
Collect post 
supplementation 
serum 25(OH)D 
level
•Compare post 
25(OH)D to 
initial draw
Data Analysis
•Evaluate effect 
of VD3 dose on 
serum 
25(OH)D. 
Increase dose?
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Appendix H 
Recruitment Script 
 
We are conducting a study led by Cristin Grant, a nurse practitioner on the liver transplant 
service here at UCLA Medical Center. The subject of the study is the effect of a vitamin D3 
protocol on our liver disease patient population.  
 
We are looking at patients with low vitamin D. You were chosen because you have a history of 
liver disease, and your vitamin D level in your blood is low. We would like to see how you 
respond after a 12-week daily supplement of vitamin D3, which will be assessed through a blood 
sample after 12 weeks.  
 
Liver disease severely affects the ability to process vitamin D, and this type of deficiency can 
contribute to many problems such as infection and poor bone health.  
 
Your consent to participate in this observational study will allow the student researcher to view 
your lab results and decide if this form of vitamin D is effective at raising blood levels in chronic 
liver disease and transplanted patients. 
 
If you chose not to participate, you will still receive vitamin D as needed.  
 
Your participation is voluntary as well as confidential. The results will assist us in improving 
care for other patients like yourself, and your help is important to us.  
 
Questions or concerns can be directed to the researcher, Cristin Grant, ACNP-BC at 
Cgrant@mednet.ucla.edu 
 
Or, If you have questions about your rights while taking part in this study, or you have concerns 
or suggestions and you want to talk to someone other than the researchers about the study, please 
call the OHRPP at (310) 825-7122 or write to:  
 
UCLA Office of the Human Research Protection Program  
11000 Kinross Avenue, Suite 211, Box 951694  
Los Angeles, CA 90095-1694  
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Appendix I 
IRB Approval Letter 
 
NOTICE OF NEW APPROVAL 
Principal Investigator: Lyla Lindholm 
UMKC Health Sciences Building 
Kansas City, MO 64108 
 
Protocol Number: 16-333 
Protocol Title: Vitamin D Supplementation in Liver Transplantation 
Type of Review: M 
 
Date of Approval: 07/27/2016 
Date of Expiration: 12/31/2999 
 
Dear Dr. Lindholm, 
 
The above referenced study, and your participation as a principal investigator, was reviewed and approved by the UMKC IRB. You are granted 
permission to conduct your study as described in your application. 
 
The above referenced study, and your participation as a principal investigator, was reviewed and determined to be Not Human Subjects Research 
(NHSR). As such, your activity falls outside the parameters of IRB review. You may conduct your study, without additional obligation to the 
IRB, as described in your application. The NHSR Determination is based upon the following Federally provided definitions: 
 
 "Research" is defined by these regulations as "a systematic investigation, including research development, testing and evaluation, designed to 
develop or contribute to generalizable knowledge." 
 
The regulations define a "Human Subject" as "a living individual about whom an investigator (whether professional or student) conducting 
research obtains: data through intervention or interaction with the individual, or identifiable private information."  
 
All Human Subjects Research must be submitted to the IRB. 
 
 If your study changes in such a way that it becomes Human Subjects Research please contact the Research Compliance office immediately for 
the appropriate course of action. 
 
This approval includes the following documents: 
 
Attachments 
 
The ability to conduct this study will expire on or before 12/31/2999 unless a request for continuing review is received and approved. If you 
intend to continue conduct of this study, it is your responsibility to provide a Continuing Review form prior to the expiration of approval. 
 
This approval is issued under the University of Missouri - Kansas City's Federal Wide Assurance FWA00005427 with the Office for Human 
Research Protections(OHRP). If you have any questions regarding your obligations under the Board's Assurance, please do not hesitate to contact 
us. 
 
There are 5 stipulations of approval: 
 
1) No subjects may be involved in any study procedure prior to the IRB approval date or after the expiration date. (PIs and sponsors are 
responsible for initiating 
Continuing Review proceedings). 
2) All unanticipated or serious adverse events must be reported to the IRB. 
3) All protocol modifications must be IRB approved prior to implementation unless they are intended to reduce risk. This includes any change of 
investigator. 
4) All protocol deviations must be reported to the IRB. 
5) All recruitment materials and methods must be approved by the IRB prior to being used. 
 
 
Please contact the Research Compliance Office (email: umkcirb@umkc.edu; phone: (816)235-5927) if you have questions or require further 
information. 
 
Thank you, 
Simon MacNeill 
TEL: 816 235-5927 
FAX: 816 235-5602 
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Appendix J 
Example of Data and Results Tables 
 
 
Patient ID Age Race Gender Etiology Pre Post CHANGE 
164 69 Hispanic F NASH 13 42 29 
767 46 Hispanic M ETOH 21 21 0 
159 68 Hispanic M ETOH 14 33 19 
290 57 Afro-Amer F ETOH 23 29 6 
189 61 Hispanic M HCV 27 37 10 
160 57 Hispanic F ETOH 19 36 17 
952 51 Caucasian M  PSC 22 35 13 
251 68 Asian M ETOH 12 47 35 
876 69 Asian M HBV/HCV 26 35  11 
430 58 Hispanic M HCV 22 28 6 
280 28 Caucasian F NASH 18 24  6 
749 68 Caucasian F HBV 22 36 14 
 
 
 
 
 
 
Pre, 18.8
Post, 32.11
% Change, 
71
0
20
40
60
80
Total (N=45)
V
it
a
m
in
 D
 n
g
/m
L
Overall Response 
0 20 40 60 80 100
Other n=9
NASH n=10
HCV n=13
ETOH n=13
Response to Vitamin D by Etiology
Pre Post % Change
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Pre: level of vitamin D prior to protocol implementation 
Post: Serum vitamin D redraw after 12 weeks of cholecalciferol  
 
 
 
 
 
 
 
 
0 10 20 30 40 50 60 70 80 90 100
Hispanic (n=24)
Caucasian (n=10)
African American (n=5)
Asian (n=6)
Response by Demographic
Pre Post %Change
0 10 20 30 40 50 60 70 80 90
Female (n=23)
Male (n=22)
Response by Gender
Pre Post %Change
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Appendix K 
Statistical Analysis Table Template, Power Analysis 
Power (95% Confidence Interval of observed proportion) by different sample sizes (n) and 
hypothesized proportions of patients who achieve normal vitamin D level after 
intervention (p), assuming we want to rule out the possibility that the proportion is 50% 
 p=0.7 p=0.75 p=0.8 p=0.85 p=0.9 
n=30     62% 
(0.54,0.86) 
    82% 
(0.6,0.9) 
    94% 
(0.66,0.94) 
    99% 
(0.72,0.98) 
    100% 
(0.79,1.01) 
n=35     68% 
(0.55,0.85) 
    87% 
(0.61,0.89) 
    97% 
(0.67,0.93) 
    100% 
(0.73,0.97) 
    100% (0.8,1) 
n=40     74% 
(0.56,0.84) 
    91% 
(0.62,0.88) 
    98% 
(0.68,0.92) 
    100% 
(0.74,0.96) 
    100% 
(0.81,0.99) 
n=45     79%  
(0.57,0.83) 
    94% 
(0.62,0.88) 
    99% 
(0.68,0.92) 
    100% 
(0.75,0.95) 
    100% 
(0.81,0.99) 
n=50     83% 
(0.57,0.83) 
    96% 
(0.63,0.87) 
    100% 
(0.69,0.91) 
    100% 
(0.75,0.95) 
    100% 
(0.82,0.98) 
n=55     86% 
(0.58,0.82) 
    97% 
(0.64,0.86) 
    100% 
(0.69,0.91) 
    100% 
(0.76,0.94) 
    100% 
(0.82,0.98) 
n=60     89% 
(0.58,0.82) 
    98% 
(0.64,0.86) 
    100% 
(0.7,0.9) 
    100% 
(0.76,0.94) 
    100% 
(0.82,0.98) 
n=65     91% 
(0.59,0.81) 
    99% 
(0.64,0.86) 
    100% 
(0.7,0.9) 
    100% 
(0.76,0.94) 
    100% 
(0.83,0.97) 
n=70     93% 
(0.59,0.81) 
    99% 
(0.65,0.85) 
    100% 
(0.71,0.89) 
    100% 
(0.77,0.93) 
    100% 
(0.83,0.97) 
n=75     95% 
(0.6,0.8) 
    99% 
(0.65,0.85) 
    100% 
(0.71,0.89) 
    100% 
(0.77,0.93) 
    100% 
(0.83,0.97) 
n=80     96% 
(0.6,0.8) 
    100% 
(0.66,0.84) 
    100% 
(0.71,0.89) 
    100% 
(0.77,0.93) 
    100% 
(0.83,0.97) 
Calculations are based on the 'pwr' package in R according to the material by Cohen, J. (1988). Statistical power 
analysis for the behavioral sciences (2nd ed.). 
This table assumes that we use a two-sided Z-test with normal approximation to make inferences about the 
proportion of a binary outcome, using 𝛼 = 0.05. 
 
Power of hypothesis test using a proportion will be the approach to calculating power. 
There is an expected proportion of 70-80% of subjects that will reach the minimum value of 
30ng/mL of serum vitamin D.  
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July 20, 2016 
 
UMKC Institutional Review Board 
University of Missouri-Kansas City 
Kansas City, MO 64108 
 
UMKC IRB,  
This letter serves to provide documentation regarding Cristin Grant’s Doctor of Nursing Practice (DNP) 
Project proposal.  Ms. Grant obtained approval for her project proposal, A Vitamin D Protocol Post 
Liver Transplantation, from the School of Nursing DNP faculty committee on July 20, 2016.   
 
If I can provide any further information, please feel free to contact me. 
Sincerely, 
 
Susan J. Kimble, DNP, RN, ANP-BC, FAANP 
Clinical Associate Professor 
DNP Programs Director 
UMKC School of Nursing and Health Studies 
816-235-5962 
kimbles@umkc.edu 
